Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090051 · ClinicalTrials.gov registry record · Phase 3
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 552
- Enrollment target
NCT00090051 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 552 participants.
The verdict
NCT00090051, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 552 participants
- Enrollment target
Study Summary
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Fludarabine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2003-07-31 |
| Est. Completion | 2012-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090051
The ClinicalTrials.gov registry entry for NCT00090051 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 552 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00090051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090051 about?
NCT00090051 is a clinical study titled "FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients". The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.
What is the current status of trial NCT00090051?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 552 participants. The study started on 2003-07-31. Estimated completion is 2012-05-31.
What interventions are being tested in trial NCT00090051?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Fludarabine Phosphate (DRUG).
Who is sponsoring clinical trial NCT00090051?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.